Superworth

AIM ImmunoTech price to sales ratio AIM

Market value divided by revenue over the last twelve months, since 2012.

Today, Nov 2, 2026
51.5×
10-year median
57.7×
Against its 10-year history
44th
percentile: 0 is its lowest day, 100 its highest
10-year range
10.0× to 198×
Peer median
1.3×

AIM ImmunoTech's price to sales ratio is 51.5× as of Nov 2, 2026.

That is below its ten-year median of 57.7×, close to the middle of its last ten years.

Over that time it ranged from 10.0× in Aug 2019 to 198× in Sep 2022.

The median for 10 healthcare stocks of a similar size is 1.3×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far51.5×17.7×82.8×
202531.8×12.0×72.6×
202466.3×60.0×130×
2023105×102×196×
2022105×105×198×
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
201910.0×10.0×58.9×
201848.7×24.4×58.9×
201726.0×23.7×194×
2016152×112×199×
2015128×112×194×
2014n/m a value too high to mean anything
2013189×140×198×
2012194×167×194×

Against its peers

Companies in Healthcare nearest AIM ImmunoTech's size, closest first, today.

Where AIM ImmunoTech ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on AIM ImmunoTech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.